文献速递妇科生殖医学

跨性别与性别多元个体长期使用睾酮治疗中突破性出血的发生率

Incidence of breakthrough bleeding in transgender and gender-diverse individuals on long-term testosterone.
PubMed 文献 · Am J Obstet Gynecol · 2024-01-04

这项单中心回顾性病历回顾纳入279例使用睾酮至少1年的跨性别与性别多元子宫在位者,34%(n=96,95%CI 29-40)曾发生突破性出血,中位首次出血时间为睾酮启动后22个月;出血者启动睾酮年龄更小、平均血清睾酮水平更低、平均雌二醇水平更高。作者建议临床医生告知所有患者突破性出血在使用睾酮第一年后仍属常见。

要点

  • 使用睾酮至少1年的跨性别与性别多元子宫在位者中,34%曾发生突破性出血,中位首次出血时间为启动后22个月。
  • 发生突破性出血者启动睾酮年龄更小(20.5岁 vs 22.0岁,P=.04),平均血清睾酮水平更低(389.14 vs 512.7 ng/dL,P=.001)。
  • 发生突破性出血者平均雌二醇水平更高(62% vs 49%,P=.003),且更可能平均睾酮水平<320 ng/dL(52% vs 48%,P=.001)。

核心结论

  • 相当一部分使用睾酮的跨性别与性别多元个体即使在使用第一年后仍会经历至少1次突破性出血。
  • 作者建议临床医生告知所有患者突破性出血在使用睾酮治疗第一年后仍属常见。

研究设计与样本

  • 经机构审查委员会批准的单一大三级中心回顾性病历回顾。
  • 纳入使用睾酮至少1年的跨性别与性别多元子宫在位者279例。
  • 采用以出血发生率为主要结局的生存分析,结合描述性分析及与出血相关因素的评估。

主要发现

  • 279例中,启动睾酮的中位年龄为22岁(四分位距19-41),中位随访时间34个月(范围12-278)。
  • 曾发生突破性出血的绝对比例为34%(n=96;95%CI 29-40)。
  • 发生突破性出血者启动睾酮年龄更小(20.5 vs 22.0岁;P=.04),平均血清睾酮水平更低(389.14 vs 512.7 ng/dL;P=.001)。
  • 发生突破性出血者更可能平均睾酮水平<320 ng/dL(52% vs 48%;P=.001),平均雌二醇水平更高(62% vs 49%;P=.003)。
  • 生存分析估计突破性出血发生率为每年0.09(95%CI 0.07-1.0);随访期间58人接受子宫切除术,而保持子宫的队列中64%最终发生突破性出血;中位首次出血时间为启动睾酮后22个月(四分位距12-201)。

临床怎么用

  • 作者建议临床医生告知所有患者突破性出血在使用睾酮治疗第一年后仍属常见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the maintenance of amenorrhea among transgender and gender-diverse individuals with uteri who are using long-term testosterone gender-affirming hormone therapy. Emerging data describe breakthrough bleeding among adolescents on long-term testosterone therapy and among adults who are seeking a gender-affirming hysterectomy. More studies are needed to better understand breakthrough bleeding patterns among transgender and gender-diverse individuals with uteri who are using testosterone, including the frequency, timing, and etiology of bleeding and how these patterns may differ between adults and younger populations. OBJECTIVE: The primary aim of this study was to characterize the incidence and patterns of breakthrough bleeding in a cohort of transgender and gender-diverse individuals who had been on testosterone for longer than 12 months and who had uteri in situ. Secondary aims included identifying the time to first bleed for those who experienced breakthrough bleeding and the risk factors associated with breakthrough bleeding while on testosterone therapy. STUDY DESIGN: This was an institutional review board-approved, single tertiary center, retrospective chart review of transgender and gender diverse individuals who had been on testosterone for at least 1 year. A primary survival analysis that evaluated the incidence of bleeding was combined with descriptive analyses and an evaluation of the factors associated with bleeding. RESULTS: Of the 279 patients included in the analysis, the median age of testosterone initiation was 22 years (interquartile range, 19-41), and the median follow-up time was 34 months (range, 12-278). The absolute proportion of individuals who ever experienced breakthrough bleeding on testosterone was 34% (n=96; 95% confidence interval, 29-40). Patients who experienced breakthrough bleeding initiated testosterone at a younger age (20.5 vs 22.0 years; P=.04), had lower mean serum testosterone levels (389.14 vs 512.7 ng/dL; P=.001), were more likely to have a mean testosterone level <320 ng/dL (52% vs 48%; P=.001), and had higher mean estradiol levels (62% vs 49%; P=.003). Survival analyses estimated a breakthrough bleeding incidence rate of 0.09 per year (95% confidence interval, 0.07-1.0). Although 58 people underwent a hysterectomy during the follow-up period, 64% of the cohort who maintained a uterus eventually experienced breakthrough bleeding. The median time to the initial bleeding episode was 22 months (interquartile range, 12-201) after testosterone initiation. CONCLUSION: These results suggest that a substantial fraction of transgender and gender-diverse individuals who are using testosterone will experience at least 1 episode of breakthrough bleeding even after their initial year of testosterone use. We recommend that clinicians inform all patients that breakthrough bleeding is a common occurrence even after the first year on testosterone therapy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Grimstad FW, Boskey ER, Clark RS, et al. Incidence of breakthrough bleeding in transgender and gender-diverse individuals on long-term testosterone. Am J Obstet Gynecol. 2024. PMID: 38181830. doi:10.1016/j.ajog.2023.12.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。